Shenzhen Zhongge Biotechnology Co. Ltd. has divulged cholesterol side-chain cleavage enzyme, mitochondrial (CYP11A1) inhibitors reported to be useful for the treatment of castration-resistant prostate cancer.
Shenzhen Zhongge Biotechnology Co. Ltd. has synthesized probable global transcription activator SNF2L2 (SMARCA2; BAF190B; SNF2-α) inhibitors reported to be useful for the treatment of cancer.
Shenzhen Zhongge Biotechnology Co. Ltd. has disclosed protein mono-ADP-ribosyltransferase TIPARP (PARP-7; ARTD14) inhibitors reported to be useful for the treatment of inflammatory disorders, immunological disorders, viral infections and cancer.
Shenzhen Zhongge Biotechnology Co. Ltd. has described proteolysis targeting chimera (PROTAC) compounds comprising an E3 ubiquitin ligase binding agent coupled to interleukin-1 receptor-associated kinase 4 (IRAK-4) targeting moiety via linkers acting as IRAK-4 degradation inducers reported to be useful for the treatment of cancer, autoimmune disease, inflammatory disorders, transplant rejection, thromboembolism, atherosclerosis, myocardial infarction and metabolic syndrome.
Shenzhen Zhongge Biotechnology Co. Ltd. has described tyrosine-protein phosphatase non-receptor type 2 (PTPN2; TCPTP) inhibitors reported to be useful for the treatment of cancer, type 2 diabetes, obesity and metabolic diseases.
Shenzhen Zhongge Biotechnology Co. Ltd. has synthesized AMP-activated protein kinase α1β1γ1 activators reported to be useful for the treatment of acute kidney injury, alopecia, chronic kidney disease, diabetes type 2, diabetic nephropathy, dyslipidemia and obesity.
Shenzhen Zhongge Biotechnology Co. Ltd. prepared and tested cholesterol side-chain cleavage enzyme, mitochondrial (CYP11A1) inhibitors reported to be useful for the treatment of castration-resistant prostate cancer.
Shenzhen Zhongge Biotechnology Co. Ltd. has synthesized serine/threonine-protein kinase ULK1 inhibitors reported to be useful for the treatment of cancer, lymphangioleiomyomatosis and tuberous sclerosis.
Shenzhen Zhongge Biotechnology Co. Ltd. has identified proteolysis targeting chimera (PROTAC) compounds comprising an E3 ubiquitin ligase binding moiety covalently linked to an interleukin-1 receptor-associated kinase 4 (IRAK-4) targeting moiety via a linker reported to be useful for the treatment of cancer, autoimmune disorders, inflammatory disorders, transplant rejection, thromboembolism, atherosclerosis, myocardial infarction and metabolic syndrome.
